Neuropace Inc reports results for the quarter ended September 30 - Earnings Summary

• Neuropace Inc NPCE.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of six analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -29 cents to -24 cents per share.

• Revenue rose 28.2% to $21.06 million from a year ago; analysts expected $19.08 million.

• Neuropace Inc's reported EPS for the quarter was a loss of 19 cents​.

• The company reported a quarterly loss of $5.45 million.

• Neuropace Inc shares had risen by 2.4% this quarter and lost 30.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Neuropace Inc is $16.00

This summary was machine generated from LSEG data November 13 at 02:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)